Mineralys Therapeutics
NASDAQ: MLYSRadnor, US · Founded 2019 · Delaware corporation · 7 known investors
Mineralys Therapeutics is a clinical-stage pharmaceutical company developing lorundrostat, a treatment targeting dysregulated aldosterone. It focuses on cardio-renal-metabolic diseases, including hypertension and chronic kidney disease.
BiotechHealthtech
Founders & leadership
EW
Eric WarrenChief Commercial Officer
AG
Alex GoldChief Medical Officer
AL
Adam LevyNamed on SEC filing
AA
Alexander AsamNamed on SEC filing
Board
BT
Brian Taylor SlingsbyFounder & former CEO / Board DirectorFounder & Managing Director, MD, PhD, MPH at Catalys Pacific
OL
DD
JC
SA
Srinivas AkkarajuBoard director
TT
Investors · 7
Reported raises · per SEC filings
Form D private placements$118M disclosed across 1 round · 2022
▶$118MraisedJun 2022 · 23 investors · PharmaceuticalsRule 506(b)
▶$118MraisedJun 2022 · 23 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Brian Taylor SlingsbyDirector
- Olivier LitzkaDirector
- Derek DiRoccoDirector
- Adam LevyExecutive Officer
- Jon CongletonExecutive Officer, Director
- Srinivas AkkarajuDirector
- Alexander AsamDirector
- Takeshi TakahashiDirector
- Offering amount
- $118M
- Amount sold
- $118M
- First sale
- Jun 2022
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapSeeking Alpha20 shared keywordsSeeking Alpha is a financial research platform that provides stock analysis, investment tools, and market coverage across asset classes to investors. The platform aggregates research from thousands of analysts and investors, offering ratings, articles, and investment ideas.
Exelixis18 shared keywordsExelixis is a biopharmaceutical company developing cancer therapies through biotherapeutics and small molecule programs, including bispecific antibodies and antibody-drug conjugates. It advances anti-cancer treatments internally and via industry collaborations across multiple modalities in biologics and small molecules.
TipRanks17 shared keywordsFinancial analysis and stock research platform.
Simply Wall St16 shared keywordsSimply Wall St is a stock analysis platform that provides portfolio insights, stock discovery tools, and market alerts for individual investors. The service offers institutional-grade financial data visualization and analysis across 120,000 global stocks.
Companies competing with Mineralys Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Mineralys Therapeutics do?
- Mineralys Therapeutics is a clinical-stage pharmaceutical company developing lorundrostat, a treatment targeting dysregulated aldosterone. It focuses on cardio-renal-metabolic diseases, including hypertension and chronic kidney disease.
- Who are Mineralys Therapeutics's investors?
- Mineralys Therapeutics's investors include Andera Partners, Samsara BioCapital, SR One Capital Management, Ysios Capital, Boulder Ventures, Catalys Pacific, RA Capital.
- How much funding has Mineralys Therapeutics raised?
- Mineralys Therapeutics has disclosed $118M raised across 1 round.
- Where is Mineralys Therapeutics headquartered?
- Mineralys Therapeutics is headquartered in Radnor, US.